Evidence map›Paper›PMID 34916590›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

A neuroeconomic signature of opioid craving: How fluctuations in craving bias drug-related and nondrug-related value.

Kathryn Biernacki, Silvia Lopez-Guzman, John C Messinger, Nidhi V Banavar, John Rotrosen, Paul W Glimcher, Anna B Konova

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Human laboratory models of reward in substance use disorder.Pharmacology, biochemistry, and behavior · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Kathryn BiernackiDepartment of Psychiatry, University Behavioral Health Care, and the Brain Health Institute, Rutgers University-New Brunswick, Piscataway, NJ, 08855, USA.ORCID http://orcid.org/0000-0003-0715-2958
Silvia Lopez-GuzmanNeuroscience Institute, NYU Grossman School of Medicine, New York, NY, 10016, USA.
John C MessingerNeuroscience Institute, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Nidhi V BanavarNeuroscience Institute, NYU Grossman School of Medicine, New York, NY, 10016, USA.
John RotrosenDepartment of Psychiatry, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Paul W Glimcher *Neuroscience Institute, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Anna B Konova *Department of Psychiatry, University Behavioral Health Care, and the Brain Health Institute, Rutgers University-New Brunswick, Piscataway, NJ, 08855, USA. anna.konova@rutgers.edu.ORCID http://orcid.org/0000-0001-8894-6164

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Decision Neuroscience of CravingR01DA054201 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI KONOVA, ANNA BORISOVA · 2021 to 2025
$2.8M
Computational psychiatry investigation of the role of unrealistic optimism in opioid use disorder and relapseR01DA053282 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI KONOVA, ANNA BORISOVA · 2021 to 2025
$2.8M
Computational neuroeconomic models of addiction: quantifying progression and treatment in opioid use disorderR01DA043676 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GLIMCHER, PAUL W, ROTROSEN, JOHN P · 2017 to 2021
$2.1M
Neuroeconomic investigation of craving in opioid addictionF32DA039648 · NIDA · NEW YORK UNIVERSITY · PI KONOVA, ANNA BORISOVA · 2015 to 2017
$164k
NIDA NIH HHS F32 DA039648NIDA NIH HHS R01 DA043676NIDA NIH HHS R01 DA053282NIDA NIH HHS R01 DA054201NIDA NIH HHS UG1 DA013035
6 · The paper itself

Abstract

How does craving bias decisions to pursue drugs over other valuable, and healthier, alternatives in addiction? To address this question, we measured the in-the-moment economic decisions of people with opioid use disorder as they experienced craving, shortly after receiving their scheduled opioid maintenance medication and ~24 h later. We found that higher cravers had higher drug-related valuation, and that moments of higher craving within-person also led to higher drug-related valuation. When experiencing increased opioid craving, participants were willing to pay more for personalized consumer items and foods more closely related to their drug use, but not for alternative "nondrug-related" but equally desirable options. This selective increase in value with craving was greater when the drug-related options were offered in higher quantities and was separable from the effects of other fluctuating psychological states like negative mood. These findings suggest that craving narrows and focuses economic motivation toward the object of craving by selectively and multiplicatively amplifying perceived value along a "drug relatedness" dimension.

Indexed as

Behavior, AddictiveOpioid-Related DisordersAffectAnalgesics, OpioidCravingHumansAnalgesics, Opioid

Identifiers

PMID34916590
PMCPMC9205977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.